Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

CytomX Therapeutics, Inc. (CTMX)

1.81   0.02 (1.12%) 11-25 13:00
Open: 1.81 Pre. Close: 1.79
High: 1.835 Low: 1.7875
Volume: 440,353 Market Cap: 120(M)

Technical analysis

as of: 2022-11-28 9:17:38 AM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 2.26     One year: 2.64
Support: Support1: 1.46    Support2: 1.16
Resistance: Resistance1: 1.94    Resistance2: 2.26
Pivot: 1.45
Moving Average: MA(5): 1.79     MA(20): 1.41
MA(100): 1.47     MA(250): 2.49
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 87.4     %D(3): 87.8
RSI: RSI(14): 69
52-week: High: 6.96  Low: 1.16
Average Vol(K): 3-Month: 1,346 (K)  10-Days: 5,862 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CTMX ] has closed below upper band by 15.5%. Bollinger Bands are 167.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.84 - 1.85 1.85 - 1.85
Low: 1.77 - 1.78 1.78 - 1.79
Close: 1.79 - 1.81 1.81 - 1.82

Company Description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Headline News

Wed, 23 Nov 2022
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update - Nasdaq

Fri, 18 Nov 2022
CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron - Zacks Investment Research

Thu, 17 Nov 2022
Healthcare Stocks Making Moves Thursday: CTMX, BDSX, TCRT, NRXP, NOTV, BVS, TNYA, IMCC - InvestorsObserver

Thu, 17 Nov 2022
Health Care Sector Update for 11/17/2022: CTMX,REGN,ARDX,TNYA,BNOX - Nasdaq

Thu, 10 Nov 2022
CytomX Therapeutics Inc (CTMX) is down 3.23% Thursday In Premarket Trading - InvestorsObserver

Thu, 10 Nov 2022
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14% - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 66 (M)
Shares Float 55 (M)
% Held by Insiders 1.2 (%)
% Held by Institutions 58.3 (%)
Shares Short 997 (K)
Shares Short P.Month 1,200 (K)

Stock Financials

EPS -1.41
EPS Est Next Qtl -0.41
EPS Est This Year -1.5
EPS Est Next Year -1.41
Book Value (p.s.) 0.43
Profit Margin (%) -135.7
Operating Margin (%) -127.5
Return on Assets (ttm) -19.2
Return on Equity (ttm) -139.3
Qtrly Rev. Growth -3.8
Gross Profit (p.s.) 1.05
Sales Per Share 1.08
EBITDA (p.s.) -1.35
Qtrly Earnings Growth 0
Operating Cash Flow -141 (M)
Levered Free Cash Flow -46 (M)

Stock Valuations

PE Ratio -1.29
PEG Ratio 1.3
Price to Book value 4.2
Price to Sales 1.66
Price to Cash Flow -0.86

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.